Tracers / [89Zr]DFO-Per-F(ab')2
[89Zr]DFO-Per-F(ab')2
Also written as [Zr-89]Zr-DFO-Per-F(ab')2
- Radionuclide
- Zr-89 t½ 4704 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- DFO-conjugated F(ab')2 antibody fragment (anti-HER2, derived from Pertuzumab)
- Target / mechanism
- HER2-targeting via Pertuzumab-derived F(ab')2 fragment PMID 42592442
- Clinical application
- —
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | SPE | — | approximately 95% | DFO-Per-F(ab')2 | 42592442 2026 Acta Pharm Sin B a mixture of 200 μL of DFO-Per, DFO-Per-F(ab')2 or DFO-Per-Fab (0.67 nmol) in 0.5 mol/L HEPES and 100 μL of [89Zr]ZrC2O4 (37 MBq) was incubated at 20 °C for 30 min |
Need this precursor?We can point you to suppliers for [89Zr]DFO-Per-F(ab')2, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 42592442. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 42592442: 'DFO-Per, DFO-Per-F(ab')2 and DFO-Per-Fab were purified using a PD-10 desalting column'.